Japan, Oct. 5 -- INHIBRX BIOSCIENCES INC has got intellectual property rights for 'DLL3 SINGLE DOMAIN ANTIBODY AND THERAPEUTIC COMPOSITION OF THE SAME.' Other related details are as follows:
Application Number: JP,2024-226838
Category (FI): C12N1/19,C12N1/15,C12N15/63@Z,C12N15/62@Z,A61K39/395@N,C12N15/13,C07K16/46,C07K16/28,A61K38/21,A61K39/395@T,C07K16/30,A61K40/31,A61K38/19,C07K14/725,A61K39/395@L,A61K47/68,A61K35/17,A61P35/00,A61P37/04,C12N5/0783,C07K14/705,C12P21/08,C12N5/10,C12N1/21
Stage: Grant (IP right granted following substantive examination.)
Filing Date: Dec. 24, 2024
Publication Date: April 10, 2025
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication....